MVA-BN filovirus vaccine - Bavarian Nordic

Drug Profile

MVA-BN filovirus vaccine - Bavarian Nordic

Alternative Names: Ebola Marburg virus vaccine - Bavarian Nordic; Marburg Ebola virus vaccine - Bavarian Nordic; Modified Vaccinia Ankara Bavarian Nordic Marburg Ebola vaccine; MVA-BN Filo; MVA-BN-EBOV-MARV; MVA-BN-MARV-EBOV

Latest Information Update: 21 Apr 2017

Price : $50

At a glance

  • Originator Bavarian Nordic
  • Developer Bavarian Nordic; Crucell
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Ebola virus infections
  • Phase II Marburg virus disease

Most Recent Events

  • 18 Apr 2017 Bavarian Nordic in-licenses EB66® cell-line technology from Valneva
  • 01 Sep 2016 National Institute of Allergy and Infectious Diseases (NIAID) plans a phase I trial for Ebola virus infection (In volunteers) in USA (NCT02891980)
  • 04 Aug 2016 Janssen Vaccines & Prevention B.V in collaboration with National Institute of Allergy and Infectious Diseases (NIAID) plans a phase I trial in Healthy volunteers in USA (NCT02860650)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top